J
James E. Shaw
Researcher at Virginia Commonwealth University
Publications - 13
Citations - 643
James E. Shaw is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Bevacizumab & Cetuximab. The author has an hindex of 7, co-authored 13 publications receiving 603 citations.
Papers
More filters
Journal ArticleDOI
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
Alan P. Venook,Donna Niedzwiecki,Heinz-Josef Lenz,Federico Innocenti,Michelle R. Mahoney,Bert H. O'Neil,James E. Shaw,Blase N. Polite,Howard S. Hochster,James N. Atkins,Richard M. Goldberg,Robert J. Mayer,Richard L. Schilsky,Monica M. Bertagnolli,Charles D. Blanke,Ecog +15 more
TL;DR: Overall OS of 29 + mos and 8% long-term survivors confirms progress in MCRC, and expanded RAS and other molecular and clinical analyses may identify subsets of pts who get more or less benefit from specific regimens.
Journal ArticleDOI
501ocalgb/swog 80405: phase iii trial of irinotecan/5-fu/leucovorin (folfiri) or oxaliplatin/5-fu/leucovorin (mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mcrc)
H. J. Lenz,Donna Niedzwiecki,Federico Innocenti,Charles D. Blanke,M.R. Mahony,Bert H. O'Neil,James E. Shaw,Blase N. Polite,Howard S. Hochster,James M Atkins,Richard M. Goldberg,Robert J. Mayer,Richard L. Schilsky,Monica M. Bertagnolli,Alan P. Venook +14 more
TL;DR: FOLFIRI or mFOLFOX6, combined with BV or CET, are 1st-line treatments for MCRC, and identified xx% mutations in kras exon 3 and 4 and NRAS in exon 2,3 and 4 in patients with wt KRAS exon2.
Journal ArticleDOI
O-0019calgb/swog 80405: phase iii trial of irinotecan/5-fu/leucovorin (folfiri) or oxaliplatin/5-fu/leucovorin (mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with kras wild-type (wt) untreated metastatic adenocarcinoma of the colon
Alan P. Venook,Donna Niedzwiecki,H. J. Lenz,Federico Innocenti,Michelle R. Mahoney,Bert H. O'Neil,James E. Shaw,Blase N. Polite,Howard S. Hochster,James M Atkins,Richard M. Goldberg,Robert J. Mayer,Richard L. Schilsky,Monica M. Bertagnolli,Charles D. Blanke +14 more
Journal ArticleDOI
Lba10calgb/swog 80405: analysis of patients undergoing surgery as part of treatment strategy
Alan P. Venook,Donna Niedzwiecki,H. J. Lenz,Michelle R. Mahoney,Federico Innocenti,Bert H. O'Neil,Howard S. Hochster,Richard M. Goldberg,Richard L. Schilsky,Robert J. Mayer,Blase N. Polite,James M Atkins,James E. Shaw,Monica M. Bertagnolli,Charles D. Blanke +14 more
TL;DR: This subset analysis is to determine the characteristics and the long-term outcome of patients enrolled on this first-line treatment study for metastatic disease but who underwent surgery following chemotherapy, to identify possible predictive characteristics and also to determine if there is an explanation for the fact that more patients on CET went to surgery than did pts on BV.
Journal ArticleDOI
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
Justin C. Brown,Sui Zhang,Fang-Shu Ou,Alan P. Venook,Donna Niedzwiecki,Heinz-Josef Lenz,Federico Innocenti,Bert H. O'Neil,James E. Shaw,Blase N. Polite,Crystal S. Denlinger,James N. Atkins,Richard M. Goldberg,Kimmie Ng,Robert J. Mayer,Charles D. Blanke,Eileen M. O'Reilly,Charles S. Fuchs,Jeffrey A. Meyerhardt +18 more
TL;DR: Diabetes is associated with an increased risk of mortality and tumor progression in patients with advanced or metastatic CRC and patients with diabetes tolerate first-line treatment with chemotherapy and monoclonal antibodies similarly to patients without diabetes.